SG11202102377YA - Combination therapies - Google Patents

Combination therapies

Info

Publication number
SG11202102377YA
SG11202102377YA SG11202102377YA SG11202102377YA SG11202102377YA SG 11202102377Y A SG11202102377Y A SG 11202102377YA SG 11202102377Y A SG11202102377Y A SG 11202102377YA SG 11202102377Y A SG11202102377Y A SG 11202102377YA SG 11202102377Y A SG11202102377Y A SG 11202102377YA
Authority
SG
Singapore
Prior art keywords
combination therapies
therapies
combination
Prior art date
Application number
SG11202102377YA
Other languages
English (en)
Inventor
Lars Engstrom
Ruth Aranda
Peter Olson
James Christensen
Jill Hallin
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of SG11202102377YA publication Critical patent/SG11202102377YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202102377YA 2018-09-10 2019-09-09 Combination therapies SG11202102377YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862729189P 2018-09-10 2018-09-10
PCT/US2019/050227 WO2020055756A1 (en) 2018-09-10 2019-09-09 Combination therapies

Publications (1)

Publication Number Publication Date
SG11202102377YA true SG11202102377YA (en) 2021-04-29

Family

ID=69778045

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102377YA SG11202102377YA (en) 2018-09-10 2019-09-09 Combination therapies

Country Status (13)

Country Link
US (1) US20220054491A1 (ru)
EP (1) EP3849538A4 (ru)
JP (1) JP2022500379A (ru)
KR (1) KR20210075981A (ru)
CN (1) CN112955137A (ru)
AU (1) AU2019340366A1 (ru)
CA (1) CA3112043A1 (ru)
EA (1) EA202190749A1 (ru)
IL (1) IL281344A (ru)
MX (1) MX2021002805A (ru)
SG (1) SG11202102377YA (ru)
WO (1) WO2020055756A1 (ru)
ZA (1) ZA202102015B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114616232A (zh) * 2019-09-06 2022-06-10 正大天晴药业集团南京顺欣制药有限公司 氮杂环庚烷并嘧啶类衍生物及其医药用途
CN112694475A (zh) * 2019-10-23 2021-04-23 苏州泽璟生物制药股份有限公司 环烷基类和杂环烷基类抑制剂及其制备方法和应用
TW202144349A (zh) * 2020-04-30 2021-12-01 大陸商上海科州藥物研發有限公司 作為kras抑制劑的雜環化合物的製備及其應用方法
BR112022026186A2 (pt) * 2020-06-25 2023-01-17 Tolremo Therapeutics Ag Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras
JP2024500326A (ja) * 2020-12-08 2024-01-09 ジェネンテック, インコーポレイテッド 固形腫瘍を治療するためのkrasg12c阻害剤及びegfr阻害剤を含む方法及び組成物
WO2022148421A1 (en) * 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
WO2023280026A1 (zh) * 2021-07-05 2023-01-12 四川科伦博泰生物医药股份有限公司 杂芳环化合物、其制备方法及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2510121A1 (en) * 2009-12-11 2012-10-17 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
US20120107304A1 (en) * 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
DK3447069T3 (da) * 2012-11-21 2020-11-16 Janssen Biotech Inc Bispecifikke egfr/c-met-antistoffer
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2017201161A1 (en) * 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
HUE061599T2 (hu) * 2017-11-15 2023-07-28 Mirati Therapeutics Inc KRas G12C inhibotorok
US10647715B2 (en) * 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors

Also Published As

Publication number Publication date
CN112955137A (zh) 2021-06-11
EA202190749A1 (ru) 2021-07-09
ZA202102015B (en) 2023-05-31
US20220054491A1 (en) 2022-02-24
JP2022500379A (ja) 2022-01-04
EP3849538A1 (en) 2021-07-21
IL281344A (en) 2021-04-29
EP3849538A4 (en) 2022-06-29
KR20210075981A (ko) 2021-06-23
WO2020055756A1 (en) 2020-03-19
CA3112043A1 (en) 2020-03-19
AU2019340366A1 (en) 2021-04-01
MX2021002805A (es) 2021-07-15

Similar Documents

Publication Publication Date Title
ZA202102016B (en) Combination therapies
IL274407A (en) Combined treatments
IL263680A (en) Combination of treatments
IL277336A (en) combined treatment
IL291659A (en) Combined treatments
EP3849535A4 (en) Combination therapies
ZA202102015B (en) Combination therapies
GB201800761D0 (en) Interaction between blockchains
EP3860609A4 (en) COMBINATION THERAPIES
EP3849536A4 (en) Combination therapies
ZA202102727B (en) Immunoablative therapies
EP3849534A4 (en) COMBINATION THERAPIES
HK1243598A1 (zh) 聯合治療
IL281526A (en) Train routing unit
EP3849537A4 (en) Combination therapies
IL280968A (en) Combined treatment
IL279908A (en) Combined treatment
IL276999A (en) Shield unit
EP3844177A4 (en) COMBINATION THERAPIES
GB201805799D0 (en) b
GB201916906D0 (en) Combination therapies
IL280729A (en) Combined treatment
GB201807046D0 (en) Combination
IL287667A (en) Combined treatments
GB201807887D0 (en) Combination